VIBATIV(TM) Approved for the Treatment of cSSSI Caused by Susceptible Gram-positive Bacteria, Including MRSA and MSSA Strains MARKHAM, ON and SOUTH SAN FRANCISCO, CA., Oct., 1 — (HSMN NewsFeed) - Astellas Pharma Canada, Inc. (Astellas) and Theravance, …
Biopharmaceuticals, Regulatory
Theravance, Astellas Pharma Canada, VIBATIV, telavancin, cSSSI, MRSA

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections”
Leave a Comment